Less than 899 patients to go!

Watch By James Heilman - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=57633908

Remember: Every minute counts

Watch By Garry Knight (Flickr: 4:06 PM) [CC BY-SA 2.0 (https://creativecommons.org/licenses/by-sa/2.0)], via Wikimedia Commonss

Traumatic Brain Injury
is a global problem

Watch By Sgt. Bryan Peterson - https://www.dvidshub.net/image/1008631, Public Domain, https://commons.wikimedia.org/w/index.php?curid=39650584

The CRASH-3 trial is a
step towards progress

Watch Credit: David Gregory & Debbie Marshall

A global collaboration

Gallery Courtesy of The CTU

Subscribe to receive the results

Subscribe Josh Estey/AusAID [CC BY 2.0 (https://creativecommons.org/licenses/by/2.0)], via Wikimedia Commons





The trial in numbers

finish 12331 Patients randomised

491 Patients randomised in the Golden hour in 2018

finish 669 Patients to recruit by 31 January 2019

WATCH

Every minute counts
Watch our videos and find out why we need to randomise and treat early

BLOG

Trial Updates
The latest news updates from our collaborating sites

NEWS

Trial News
The latest newsletters from the Clinical Trials Unit

SUBSCRIBE

Receive the trial results
Register your interest in the trial and subscribe to our mailing list to receive notification of the trial results and updates.

LATEST BLOG POSTS

 

 

12,331 patients recruited

28 recruiting countries

171 hospitals and medical centres

ABOUT THE TRIAL

The CRASH3 trial aims to provide the research based information to prevent death by Traumatic Brain Injury.

The CRASH3 trial is testing whether tranexamic acid, a blood clot stabiliser that was discovered in Japan in the 1950’s, can become an essential tool for fighting excessive bleeding in the brain after Traumatic Brain Injury.

more info

PATIENT INFORMATION

If you were a patient randomised into this trial and would like further information about your treatment, click below.

The staff at the hospital where you were being treated for your traumatic brain injury should have given you an information leaflet about the CRASH3 trial. If you have any questions or concerns about your treatment in the hospital, please contact your doctor in the first instance.

more info